Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.